AI-Supported Cognitive Rehabilitation for Mild Cognitive Impairment

(ReMind-AI Trial)

Age: 65+
Sex: Any
Trial Phase: Academic
Sponsor: Kaiser Permanente
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

Mild cognitive impairment (MCI) is associated with increased risk of progression to dementia, highlighting the need for accessible interventions to support cognitive health.

This randomized controlled trial will evaluate the safety and efficacy of a 12-month artificial intelligence (AI)-supported cognitive rehabilitation program for older adults with MCI. Participants will be recruited from an existing research study conducted within Kaiser Permanente Southern California and randomized 1:1 to either (1) AI-supported cognitive rehabilitation or (2) usual care alone.

The intervention combines clinician-delivered telehealth cognitive rehabilitation sessions with daily AI-guided cognitive exercises and education. The primary outcome is change in global cognition at 6 months measured by the Montreal Cognitive Assessment (MoCA)-BLIND. Secondary outcomes at 6 and 12 months include additional measures of cognition, subjective memory, goal attainment, mood, and loneliness. Exploratory outcomes include engagement with the AI intervention and health-related behavioral outcomes derived from electronic health record data.

Participant safety will be monitored throughout the study through adverse event tracking, review of AI interactions for safety concerns, and predefined procedures for responding to psychological or clinical risk.

This study will determine whether integrating AI-guided cognitive exercises with clinician-delivered rehabilitation improves cognitive and related outcomes in older adults with MCI compared to usual care.

Who Is on the Research Team?

HN

Huong Nguyen, PhD

Principal Investigator

Kaiser Permanente

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 65 years old or older.
I have been diagnosed with mild cognitive impairment.
English fluency sufficient to complete study assessments and participate in intervention sessions
See 3 more

Exclusion Criteria

Current receipt of ongoing behavioral health treatment or psychotherapy from a Kaiser Permanente clinician
Diagnosis of bipolar disorder, schizophrenia spectrum disorder, or other serious mental illness that would interfere with participation
I do not have major communication problems that stop me from joining sessions.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a 12-month AI-supported cognitive rehabilitation program, including clinician-delivered telehealth sessions and daily AI-guided cognitive exercises

12 months
Bi-weekly telehealth sessions for 6 months, monthly thereafter

Follow-up

Participants are monitored for safety and effectiveness after treatment, with assessments at 6 and 12 months

6 months
Assessments at 6 and 12 months

What Are the Treatments Tested in This Trial?

Interventions

  • AI-Supported Cognitive Rehabilitation

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: AI-Supported Cognitive RehabilitationExperimental Treatment1 Intervention
Group II: Usual CareActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Kaiser Permanente

Lead Sponsor

Trials
563
Recruited
27,400,000+

NewDays, Inc.

Collaborator